M5049 low dose
MS200569_0048
Phase 2 small_molecule active
Quick answer
M5049 low dose for Systemic Lupus Erythematosus is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Systemic Lupus Erythematosus
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active